Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK

BGB-3111, a novel Bruton’s tyrosine kinase (BTK) inhibitor, shows promising anti-cancer effects in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), and Waldenstrom macroglobulinemia (WM). This study aimed to investigate the anti-cancer effects of BGB-311...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xianhuo, Fei, Yue, Liu, Xia, Zhang, Tingting, Li, Wei, Jia, Xiaohui, Liu, Xianming, Qiu, Lihua, Qian, Zhengzi, Zhou, Shiyong, Ren, Xiubao, Zhai, Qiongli, Meng, Bin, Li, Lanfang, Zhang, Huilai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457562/
https://www.ncbi.nlm.nih.gov/pubmed/34508613
http://dx.doi.org/10.18632/aging.203314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457562/
https://www.ncbi.nlm.nih.gov/pubmed/34508613
http://dx.doi.org/10.18632/aging.203314

Ejemplares similares